Related news:
Eisai eyes fiscal 2025 U.S. approval for home version of Alzheimer's drug - Patients on Alzheimer's drug Leqembi see benefits over three years, Eisai study says - European drug regulator rejects Alzheimer's treatment Leqembi from Biogen, Eisai - Japan's Eisai aims for 2030 U.S. release of new Alzheimer's drug - Eisai to offer Alzheimer's drug in China from July - Eisai seeks expanded use of Alzheimer's drug for prevention - After US approval, Japan OKs its first Alzheimer's drug. Leqembi was developed by Eisai and Biogen
Eisai.Eu
Bookmark
ShareEisai.Eu is a company. It is located in Hatfield, the United Kingdom. The company is part of the Health Care sector, specifically in the Pharmaceuticals industry.
Key facts
- city: Hatfield
- country: United Kingdom
- sector: Health Care
- industry: Pharmaceuticals
Classified as: organization
Business
Eisai.Eu is one of the companies in the United Kingdom, companies in Pharmaceuticals, companies in Health Care and 3,466,499 companies in our database.
- Employees:
Try Pro to see estimates
- Revenues:
Try Pro to see estimates
Stocks from Eisai.Eu:
Talking Points:
- Eisai Europe
- Our work at Eisai prioritises patients and their families through our focus to continually improve the benefits that health care can provide.
- Welcome to the Eisai EMEA. Eisai (pronounced 'ā-zī') is derived from the Japanese word for 'health product' and, here at Eisai, we discover, develop and market innovative, high quality medicines throughout the world. Eisai is one of the world's leading research-based pharmaceutical companies.
Learn more about talking points
